Quantcast
Home > Quotes > ARDM
ARDM

Aradigm Corporation Common Stock (ARDM) Quote & Summary Data

$1
*  
unch
unch
Get ARDM Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading ARDM now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 1.09 / $ 0.902
Share Volume
73,082
50 Day Avg. Daily Volume
59,144
Previous Close
$ 1
52 Week High / Low
$ 7.3512 / $ 1
Market Cap
15,201,222
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
3.04

Intraday Chart

Shares Traded

Share Volume:
73,082
50 Day Avg. Daily Volume:
59,144

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.09

Trading Range

The current last sale of $1 Equals the 52 week low.

Intraday Last 52 Weeks
High: $ 1.09 $ 7.3512
 Low: $ 0.902 $ 1

Company Description (as filed with the SEC)

Aradigm Corporation (the "Company," "our company," "we," "our," or "us") are an emerging specialty pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Over the last decade, we invested a large amount of capital to develop drug delivery technologies, particularly the development of a significant amount of expertise in respiratory (pulmonary) drug delivery as incorporated in our lead product candidate that recently completed two Phase 3 clinical trials, Linhaliq inhaled ciprofloxacin, formerly known as Pulmaquin┬«. The key asset we have focused our efforts on in recent years is our inhaled ciprofloxacin formulations. We believe that our cash and cash equivalents of approximately $7.1 million as of December 31, 2017, will only be sufficient to fund our operations for the first quarter of 2018.  ... More ...  


Risk Grade

Where does ARDM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.07
Open Date:
Nov. 16, 2018
Close Price:
$ 1
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x